Kornimate/medical-research-clean huggingface dataset:
preimplantation genetic screening in women of advanced maternal age

Conditions: Chromosomal Abnormalities

Summary: an increased incidence of aneuploid pregnancies has been reported in women of advanced maternal age, with higher miscarriage rates. cytogenetic studies in preimplantation embryos have shown elevated aneuploidy rate, particularly in women over 38 years. for these reasons, pgs has been applied to these patients to improve ongoing implantation rates, and most importantly, to decrease the risk of further miscarriages and affected offspring. in the past two years, several rct have raised the question whether pgs is benefitial or not in ama patients. in our experience, pgs outcome in these patients offers higher ongoing implantation rates than the previously published in rct studies, where no benefits for pgs were found. in these papers, poor technical skills, as well as unclear patients selection could explain the reported lack of pgs benefits. therefore, the objective of the present rct is to analyze the outcome of ivf cycles with and without pgs in two age groups: * patients 38-39 years of age: 200 cyles per arm reaching embryo transfer should be performed * patients 40-44 years of age: 120 cycles per arm reaching embryo transfer sample size has been calculated according to our retrospective experience with higher differences in ongoing implantation rates between cycles with and without pgs in patients of 40-44 years of age. in all patients embryo transfer will be performed on day 5. in the pgs group one cell will be biopsy in embryos with ≥5 cells on day-3 and chromosomes 13, 15, 17, 18, 21, 22, x and y will be analyzed in two rounds. in the third round, nuclei with undoubtful or non-conclusive results will be analyzed using subtelomeric probes.


Eligibility criteria:
inclusion criteria: * female patients over 37 years old, attending a fertility clinic exclusion criteria: * azoospermic partners * female patients with uterine malformations * number of retreived oocytes below 5

Keywords: chromosomal abnormalities in preimplantation embryos
a study of ciltacabtagene autoleucel and talquetamab for the treatment of participants with high-risk multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of this study is to define the safety of ciltacabtagene autoleucel (cilta-cel) and talquetamab in participants with high-risk multiple myeloma (mm).


Eligibility criteria:
inclusion criteria: * documented diagnosis of mm according to the imwg diagnostic criteria and is defined as a measurable disease at screening * cohort 1: received at least 3 prior lines of antimyeloma therapy and have undergone greater than or equal to (\>=) 1 complete cycle of the therapy * cohort 1: documented evidence of progression of disease (pd) or failure to achieve a response to the last line of therapy * eastern cooperative oncology group (ecog) performance status score of 0 or 1 * participant of childbearing potential (pocbp) must have a negative pregnancy test using a highly sensitive β-human chorionic gonadotropin (hcg) serum pregnancy test at screening exclusion criteria: * cohort 1: prior treatment with chimeric antigen receptor t cell (car-t) therapy directed at any target or any prior b cell maturation antigen (bcma)-directed therapy/prior g protein-coupled receptor family c group 5 member d (gprc5d)-directed therapy * cohort 1: received either of the following: an allogenic stem cell transplant within 6 months before apheresis/first dose of study drug and no immunosuppressive medications administered before the start of study treatment. and secondly, received an autologous stem cell transplant less than (\<)12 weeks before apheresis/first dose of study treatment * receive live, attenuated vaccine within 4 weeks of enrollment * toxicity from previous anticancer therapy not resolved to baseline levels or to grade 1 or less except for alopecia or peripheral neuropathy * stroke, transient ischemic attack, or seizure within 6 months of signing informed consent form
effects of prostacyclin infusion on cerebral vessels and metabolism in patients with subarachnoid haemorrhage

Conditions: Subarachnoid Hemorrhage

Summary: the purpose of this study is to determine whether prostacyclin is effective in prevention of cerebral vasospasm in patients with subarachnoidal hemorrhage (sah).


Eligibility criteria:
inclusion criteria: * sah verified by ct * aneurysm identified and treated * fisher grade 3 + 4 * wfns grade 1-4 (world federation of neurosurgical societies ) exclusion criteria: * pregnancy/lactation * heard failure * kidney failure * liver failure * hemorrhagic diathesis

Keywords: subarachnoid hemorrhage vasospasm prostacyclin
high-load blood flow restriction (bfr) training may decrease anaerobic fatigue in distance runners

Conditions: Anaerobic Performance

Summary: this study investigates the effects of high-load bfr training on anaerobic performance and fatigue resistance in distance runners. to determine whether adding bfr to isokinetic resistance training improves anaerobic performance and 5-10 km running times in runners. forty-two runners were randomized into bfr (n=21) and control (n=21) groups. both groups followed an identical 8-week isokinetic training protocol twice weekly. the bfr group performed exercises with arterial occlusion pressure set to 80% of the measured occlusion pressure. anaerobic performance was assessed via the wingate test, and 5 km and 10 km running times were recorded before and after the intervention. statistical analyses compared pre- and post-training performance within and between groups.

blood flow restriction (bfr) training is increasingly used to enhance athletic performance, but its effects on anaerobic fatigue in distance runners remain unclear. this study investigates the effects of high-load bfr training on anaerobic performance and fatigue resistance in distance runners.to determine whether adding bfr to isokinetic resistance training improves anaerobic performance and 5-10 km running times in runners. forty-two runners were randomized into bfr (n=21) and control (n=21) groups. both groups followed an identical 8-week isokinetic training protocol twice weekly. the bfr group performed exercises with arterial occlusion pressure set to 80% of the measured occlusion pressure. anaerobic performance was assessed via the wingate test, and 5 km and 10 km running times were recorded before and after the intervention. statistical analyses compared pre- and post-training performance within and between groups.

Eligibility criteria:
inclusion criteria: * the absence of cardiovascular or musculoskeletal conditions, * no recent resistance training, * running more than 20 kilometers per week. exclusion criteria: * having a cardiovascular or musculoskeletal condition, * having done recent resistance training, * running less than 20 kilometers per week.

Keywords: athlete muscular kaatsu sports medicine performance
tace plus multikinase inhibitor and i-125 seeds brachytherapy for hcc with branch pvtt

Conditions: Hepatocellular Carcinoma Non-resectable

Summary: this study is conducted to evaluate the efficacy and safety of transarterial chemoembolization (tace) combined with lenvatinib and iodion-125 seeds brachytherapy (tace-len-i) compared with tace combined with lenvatinib (tace-len) for hepatocellular carcinoma (hcc) with portal vein branch tumor thrombus (branch pvtt).

this is an single center, randomized controlled trial to evaluate the efficacy and safety of tace-len-i compared with tace-len for the treatment of hcc with branch pvtt. 171 hcc patients with branch pvtt will be enrolled in this study. the patients will be treated with tace-len-i or tace-len using an 2:1 randomization scheme. tace will be performed for the patients after randomization. lenvatinib (body weight ≥ 60 kg, 12mg p.o. qd; body weight \< 60 kg, 8mg p.o. qd) will be started at 3-7 days after the first tace and last until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first. for patients in the tace-len-i arm, iodion-125 seeds will be implanted into the pvtt (according to the pre-operative planning) under ct guidance within 14 days after the first tace. tace and iodion-125 seeds implantation can be repeated on demand during follow-up based on the evaluation of laboratory and imaging examination.

Eligibility criteria:
inclusion criteria: 1. age between18 and 75 years. 2. hcc confirmed by histopathology and/or cytology, or diagnosed clinically. 3. accompanied with tumor thrombus involving unilateral portal vein branch. 4. child-pugh class a or b. 5. eastern cooperative group performance status (ecog) score of 0-2. 6. serum bilirubin ≤ 51.3 μmol/l, albumin ≥ 28g/l, alt and ast ≤ 5 times of the upper normal limit, and creatinine ≤ 20g/l. 7. prothrombin time prolonged for less than 4s or international normalized ratio \< 1.7. 8. neutrophilic granulocyte count ≥ 1.5×10\^9/l, platelet count ≥ 50×10\^9/l, and hemoglobin level ≥ 85g/l; 9. at least one measurable intrahepatic target lesion. 10. life expectancy of at least 3 months. exclusion criteria: 1. diffuse hcc. 2. extrahepatic metastasis. 3. tumor thrombus involving both the left and right branch of portal vein or main portal vein. 4. hepatic vein and/or vena cava invasion. 5. history of organ or cells transplantation. 6. previous treatment with tace, intra-arterial infusion chemotherapy, radiotherapy or systemic therapy. 7. history of other malignancies. 8. serious medical comorbidities. 9. female patients who are pregnancy or breastfeeding.

Keywords: hepatocellular carcinoma transarterial chemoembolization tyrosine kinase inhibitor iodion-125 seed
the effect of clear masks in improving patient relationships

Conditions: Communication; Trust; Covid19; Surgery

Summary: to evaluate the effect of wearing masks that hide a surgeon's facial features versus one that shows them. new patients with no prior relationship with the surgeon will be asked questions regarding communication and trust with the surgeon.

surgeons within the university of north carolina department of surgery will be recruited via an email list-serve. this recruitment email will describe the study and have the consent attached. if the surgeons are interested in participating they will respond to the email and sign the consent form. the project personnel will arrange to attend their clinic that has new patients scheduled. a random group generator will be used to randomize the patients. the surgeons will be provided either a transparent mask that demonstrates their full facial features or their typical mask that covers their mouth, for each new patient visit. following each visit, the surgeon will tell the project personnel that they are complete and the project personnel will enter the room, introduce the project, obtain verbal consent (enroll the patient) and if agreeable, provide a brief verbal survey to the patient. the survey will entail confidential questions regarding basic demographics, surgeon communication and trust, as well as an impression of the masks. survey answers will be likert scale and open ended. patients will also be given a debriefing form at the completion of their participation. surgeons will be asked their impression of the mask at the completion of their participation. all data will be kept confidential on password protected devices. if patients do not agree to the study they will not be included. if surgeons feel uncomfortable at any point they may withdraw from the study. any patient demonstrating concerning symptoms of an infection will not be included in the study. the investigators expect to recruit 10 surgeons, with 10 patients each, totally 100 patients (50 in each arm, clear vs. covered mask). using mann-whitney u test, data will be analyzed for differences in responses between the two groups. demographic data for both the patient and surgeon will also be analyzed. patient comments will be qualitatively analyzed for themes by trained researchers.

Eligibility criteria:
inclusion criteria surgeon: * faculty within department of surgery at the university of north carolina at chapel hill * must be english speaking * plans to see new in person visits in clinic exclusion criteria surgeon: * none inclusion criteria patient: * at least 18 years old * can understand and speak english without the use of an interpreter * has capacity to make independent medical decisions exclusion criteria surgeon: * has a prior relationship with the surgeon * has symptoms of a respiratory infection (cough, shortness of breath, fever)

Keywords: masks
perennial allergic rhinitis in pediatric subjects

Conditions: Rhinitis, Allergic, Perennial

Summary: to assess the safety of long-term use of cetirizine dry syrup in children with perennial allergic rhinitis.


Eligibility criteria:
inclusion criteria: * children with perennial allergic rhinitis. * giving informed consent. * children with a positive response to specific ige antibody test. * children assessed as positive in the nasal eosinophil count. * children whose severity score of nasal symptom is 4 or higher. exclusion criteria: * have a history of drug hypersensitivity. * are pregnant, lactating or possibly pregnant female children. * sensitivity to pollen as a duplicate allergen and whose treatment periods are thought in the pollen dispersion periods. * have vasomotor rhinitis and eosinophilic rhinitis. * have asthma that requires the treatment with corticosteroid. * have inappropriate complication of nasal disorder that may influence on the evaluation of the study drugs. * have complicated with atopic dermatitis or urticaria that requires the treatment with antihistamine preparation. * have started specific desensitization treatment. * nonspecific modulation treatment but who have not reached the maintenance level of treatment. * have received surgical treatment for reduction and modulation of nasal mucosa. * redintegration therapy of nasal cavity to improve the degree of nasal airway. * surgical operation to improve rhinorrhea.

Keywords: perennial allergic rhinitis pediatric
immunologic effects of echinacea

Conditions: Upper Respiratory Tract Infections

Summary: the goal of this study is to determine if echinacea purpurea stimulates the immune system. for the study, 20 healthy adults will be randomized to receive echinacea purpurea or placebo for 10 days. blood will be drawn to assess immune markers just before beginning the study medication, during the 10 day course of medication and after completing the course of medication. it is postulated that adults receiving the echinacea will have evidence of immune stimulation and those receiving placebo will not.


Eligibility criteria:
inclusion criteria: * healthy adults 21-65 years old * if female of child-bearing potential, willing to use contraception to prevent pregnancy * speaks and reads english * no use of any medication (other than multivitamins, essential fatty acids or probiotics) * willing to abstain from ingesting edible mushrooms throughout study * willing to eat less than 2 garlic cloves per day throughout study exclusion criteria: * positive pregnancy test or currently breastfeeding * history of autoimmune disease * history of allergic rhinitis * history of physician diagnosed eczema * known allergic reaction to echinacea or related species, specifically ragweed (ambrosia), chamomile (matricaria), goldenrod (solidago) and sunflower (helianthus) * use of any medication within 30 days prior to first dose of study medication that is a known inhibitor or inducer of cyp34a

Keywords: echinacea prevention immune modulation
study on optimal oxygen concentration during pulmonary rehabilitation

Conditions: High-flow Nasal Cannula; Exercise Capacity; Chronic Respiratory Failure; Optimal SpO2 Value

Summary: the purpose of this study is to compare the exercise capacity between high spo2 (minimum spo2 94-96%) value during pulmonary rehabilitation and low spo2 (minimum spo2 84-86%) value during pulmonary rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.

in patients with chronic respiratory failure, pulmonary rehabilitation is recognized as an evidence-based treatment in improving exercise capacity, muscle strength, dyspnea, and quality of life. however, optimal spo2 value during pulmonary rehabilitation in patients with chronic respiratory failure receiving long-term oxygen therapy is unclear. the present study is randomized to compare the effect of exercise capacity between high spo2 (minimum spo2 94-96%) value during pulmonary rehabilitation and low spo2 (minimum spo2 84-86%) value during pulmonary rehabilitation for the patients with chronic respiratory failure receiving long-term oxygen therapy.

Eligibility criteria:
inclusion criteria: * subjects with chronic respiratory failure receiving long-term oxygen therapy for more than 3 months. exclusion criteria: * subjects with severe cardiovascular disease, liver disease, neurological disease, and renal failure. * subjects with a history of hospitalization for pneumonia or exacerbation of respiratory failure within the last month. * subjects with changes in ltot prescription flow within the last month * subjects who cannot undergo pulmonary rehabilitation due to severe heart failure, arteriosclerosis obliterans or spinal disease.

Keywords: hfnc 6mwd
physical training in sarcoidosis patients

Conditions: Sarcoidosis

Summary: exercise intolerance, muscle weakness and fatigue complaints are frequent and persistent problems in sarcoidosis. these physical impairments are disabling and affect quality of life in a negative way. the aetiology of these physical impairments is multifactorial. physical inactivity can cause deconditioning, resulting in more perceived fatigue and muscle weakness. these symptoms may be partially reversible following a structured physical training program. however, scientific studies about physical training in sarcoidosis are lacking. therefore, the aim of the present study is to examine the changes in fatigue complaints, physical functioning and quality of life (qol) in patients with sarcoidosis following a 13-week physical training program. after obtaining written informed consent, sarcoidosis patients will start a 13-week physical training program for three times a week. this training program includes peripheral muscle training for both the upper and lower extremities (starting at 40% of the multiple-repetition maximum) and endurance training consisting of walking on a treadmill (starting at 60% of the speed of the 6-minute walk test) or cycling on a ergometer (starting at 50% of the wmax). participants will be assessed at baseline (week 0), at the end (13 weeks) and 3 months after ending the training. during these assessments, patients perform muscle strength (m. quadriceps and m. biceps) and exercise tests (six-minute walk test and submaximal endurance cycling test). they also complete several questionnaires: fatigue assessment scale (fas), world health organization quality of life assessment instrument-bref (whoqol-bref), small fiber neuropathy screening list (sfnsl), medical research council (mrc), visual analogue scale (vas) and hospital anxiety and depression scale (hads)


Eligibility criteria:
inclusion criteria: * patients are diagnosed with sarcoidosis according to the wasog guideline. * fatigued patients ((fas-score ≥ 22 points) and/or a reduced six-minute walking distance (predicted six-minute walking distance -50 m). * patients who signed the consent form and are able to participate in a training program. * minimum age 18 years and maximum age 70 years. * clinically stable: no exacerbation of complaints, or changes in initiated therapeutic management during the preceding 3 months. exclusion criteria: * patients with a cognitive failure, making them unable to understand questionnaires and instructions. * patients with a oncological, cardiac, neurological or orthopedic history making them unable to participate in a training program. * patients who are unfamiliar with the dutch language, disabling them to understand questionnaires and instructions. * patients who participated in a physical training program six months prior to inclusion.

Keywords: training program resistance training endurance training muscle strength exercise capacity fatigue quality of life
increasing prep with trans women in the deep south

Conditions: Hiv

Summary: the goal of this to address barriers and facilitators to prep uptake, and encourage adherence among trans women via a single arm stepped wedge clinical trial. the main question is to compare prep uptake and adherence outcomes among trans women in the t'cher intervention to the delayed study arm.

the intervention will also assess changes in health care empowerment and support for social determinants of health (sdoh) as mediating the effect of the intervention on prep uptake and adherence among trans women.

Eligibility criteria:
inclusion criteria: * provision of signed and dated informed consent form * declaration of willingness to comply with all study procedures and availability during the study * age 18 years old or older * male sex designated at birth * identify as trans woman, woman or another gender identity not associated with being a man * desire to use or re-start prep * hiv uninfected * speaks english or spanish * live in the new orleans metropolitan statistical area (which includes 8 parishes) exclusion criteria: * confirmed hiv infection by rapid algorithm testing and/or laboratory testing (described above) * prior or current participation in the active arm of an hiv vaccine trial with evidence of vaccine-induced seropositivity * concurrent or planned enrollment in a research study that provides prep * unwilling to attend quarterly follow-up visits, which will include survey participation * has any other condition which, based on the opinion of the investigator, would preclude provision of informed consent; make participation in the project unsafe; complicate interpretation of outcome data; or otherwise interfere with achieving the project objectives